• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

N,N-对二(2-氯乙基)氨基苯酚、N,N-对二(2-氯乙基)氨基苯基磷酸酯及其他双功能氮芥对人前列腺肿瘤酸性磷酸酶的抑制作用

Inhibition of human prostatic tumour acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustards.

作者信息

Workman P

出版信息

Chem Biol Interact. 1978 Jan;20(1):103-12. doi: 10.1016/0009-2797(78)90085-6.

DOI:10.1016/0009-2797(78)90085-6
PMID:630640
Abstract

Potent inhibition of human prostatic carcinoma tissue acid phosphatase by N,N-d-di-2-chloroethylaminophenol (AMOH) and N,N-p-di-2-chloroethylaminophenyl phosphate (AMPh) is described. Certain other difunctional nitrogen mustards were also inhibitory but N,N-p-di-2hydroxyethylaminophenol, the non-alkylating fully hydrolysed product from AMOH, was not. Inactivation of the enzyme by AMPh was progressive with time, showed apparent first order reaction kinetics and was not reversed by extensive dialysis. The results suggest that the inability of the enzyme to catalyse the hydrolysis of AMPh was due to inhibition in the presence of AMPh, possibly involving an alkylating mechanism. The implications for possible chemotherapy with AMPh are discussed.

摘要

本文描述了N,N-二(2-氯乙基)氨基苯酚(AMOH)和N,N-对二(2-氯乙基)氨基苯基磷酸酯(AMPh)对人前列腺癌组织酸性磷酸酶的强效抑制作用。某些其他双功能氮芥也具有抑制作用,但AMOH的非烷基化完全水解产物N,N-对二(2-羟乙基)氨基苯酚则没有抑制作用。AMPh对该酶的失活作用随时间逐渐增强,呈现明显的一级反应动力学,且通过广泛透析不能逆转。结果表明,该酶无法催化AMPh水解是由于在AMPh存在下受到抑制,可能涉及烷基化机制。文中还讨论了AMPh在可能的化疗中的意义。

相似文献

1
Inhibition of human prostatic tumour acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustards.N,N-对二(2-氯乙基)氨基苯酚、N,N-对二(2-氯乙基)氨基苯基磷酸酯及其他双功能氮芥对人前列腺肿瘤酸性磷酸酶的抑制作用
Chem Biol Interact. 1978 Jan;20(1):103-12. doi: 10.1016/0009-2797(78)90085-6.
2
Enzyme activated anti-tumor agents--IV. Comparative kinetics of N,N-p-di-2-chloroethylaminophenyl phosphate hydrolysis catalysed by phosphatases of normal and neoplastic tissues.酶激活抗肿瘤剂——IV. 正常组织和肿瘤组织磷酸酶催化的N,N-对-二(2-氯乙基)氨基苯基磷酸酯水解的比较动力学
Biochem Pharmacol. 1978 Jan 15;27(2):199-202. doi: 10.1016/0006-2952(78)90301-5.
3
Synthesis and preliminary characterization of a novel substrate for gamma-glutamyl transferase. A potential anti-hepatoma drug.一种新型γ-谷氨酰转移酶底物的合成与初步表征。一种潜在的抗肝癌药物。
Biochem Pharmacol. 1984 Feb 15;33(4):527-9. doi: 10.1016/0006-2952(84)90302-2.
4
Structure-activity relationship of aniline mustards acting against B-16 melanoma in mice.苯胺氮芥对小鼠B-16黑色素瘤的构效关系。
J Med Chem. 1979 Oct;22(10):1267-9. doi: 10.1021/jm00196a023.
5
Structure-activity relationships in antitumor aniline mustards.
J Med Chem. 1978 Jan;21(1):16-26. doi: 10.1021/jm00199a004.
6
Estracyt (NSC 89199) as a substrate for phosphatases in human serum.雌莫司汀(NSC 89199)作为人血清中磷酸酶的底物。
Invest Urol. 1974 Jul;12(1):38-9.
7
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.DNA 导向的烷化剂。1. 吖啶连接的苯胺氮芥的构效关系:改变氮芥反应性的影响
J Med Chem. 1990 Apr;33(4):1177-86. doi: 10.1021/jm00166a015.
8
Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.在基因导向酶前药治疗系统中,可被羧肽酶G2裂解产生3,5-二氟苯酚和苯胺氮芥的前药之间,生物学参数存在显著差异。
J Med Chem. 2004 May 6;47(10):2651-8. doi: 10.1021/jm030966w.
9
[In vitro studies of the antitumor effect of melphalan and analogous aniline mustard derivatives].[美法仑及类似苯胺氮芥衍生物抗肿瘤作用的体外研究]
Arch Pharm (Weinheim). 1989 Sep;322(9):517-21. doi: 10.1002/ardp.19893220902.
10
Cytotoxicity of aniline mustard glucuronide alone or in a combination with glucose in Walker cells in culture and sarcoma-180 tumour bearing animals.
Biomed Pharmacother. 1983;37(7):339-43.

引用本文的文献

1
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.汤姆·康纳斯教授与英国癌症研究中心I/II期临床试验委员会新型癌症疗法的研发。
Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106.